LTR Pharma (ASX:LTP) completed the data evaluation phase of its clinical study on SPONTAN, its intranasal formulation of erectile dysfunction medication vardenafil, according to a Monday filing with the Australian Securities Exchange.

The study found that SPONTAN nasal spray had a 470% faster absorption rate than oral tablets and was well-tolerated with no serious adverse events, the filing said.

LTR Pharma shares were down nearly 2% in midday trade Tuesday.